U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593248) titled 'Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China' on May 12.
Brief Summary: This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.
Study Start Date: June 30
Study Type: OBSERVATIONAL
Condition:
Lung Cancer
Recruitment Status: NOT_YET_RECRUI...